From GlobeNewswire:

=0.0033), and a Win Ratio of 1.8 (p=0.0033) on the key secondary endpoint composite of ACM and CVH, compared to placebo.

– Acoramidis showed a significant treatment effect in a study, with a Win Ratio of 1.8 (p=0.0033) on the primary endpoint and a Win Ratio of 1.8 (p=0.0033) on the key secondary endpoint compared to placebo, demonstrating a positive impact on all-cause mortality and frequency of cardiovascular-related hospitalization.

– Results from a recent study show that Acoramidis had a significant treatment effect on the primary and secondary endpoints, with a Win Ratio of 1.8 (p=0.0033) compared to placebo, indicating a positive impact on all-cause mortality and frequency of cardiovascular-related hospitalization.



Read more: BridgeBio Pharma Announces Publication of Positive Results